Eleva

Quick links to important sections

Eleva

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eleva

What is Eleva? Definition and Classification

Eleva is a prescription-only medicine containing the active substance Sertraline, formulated as its chemically stable salt, Sertraline Hydrochloride. This compound is classified as a Selective Serotonin Reuptake Inhibitor (SSRI), which belongs to the broader group of antidepressant agents utilized for their role in supporting mood regulation. This classification is identified for its application within the Central Nervous System (CNS) to address specific neurochemical mechanisms.

Sertraline Hydrochloride: Composition, Form, and Origin

Sertraline is a synthetic chemical compound, not derived from natural sources, and is consistently supplied as a single-entity product. While the Sertraline molecule is the core therapeutic agent, Eleva is a specific formulation typically manufactured as an oral tablet for consistent administration. The choice of the oral route and the stabilized Hydrochloride salt is intended to support the drug's predictable absorption. The Sertraline molecule is chemically distinct within the SSRI class, contributing to its profile of wide clinical use globally.

The General Purpose of an SSRI

Consistent with its classification, the general purpose of Eleva is to support emotional and psychological stability by regulating the availability of the neurotransmitter serotonin in the brain. It functions by selectively blocking the reuptake of serotonin into nerve cells. This pharmacological action is intended to promote stability in mood and emotional regulation, serving as a tool for individuals requiring sustained support for their neurochemical balance.

Regulatory References

  1. Sertraline - StatPearls (NIH)
  2. Sertraline: MedlinePlus Drug Information (NIH)

What side effects are possible with Eleva?

Official Safety Profile and Adverse Reactions

The official safety profile of Eleva (Sertraline) is structured around categories of possible adverse reactions as defined in government regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC). These classifications reflect the frequency and physiological system affected, establishing a formal risk framework.

Frequency-Classified Adverse Reactions

The regulatory labeling defines the following expected rates of occurrence:

  • Very Common (occurring in ge1 in 10 patients): Nausea, insomnia, headache (often noted at treatment initiation), dry mouth, and ejaculation failure.
  • Common (occurring in ge1 in 100 but <1 in 10 patients): Diarrhea/loose stools, decreased appetite, somnolence (drowsiness), dizziness, tremor, hyperhidrosis (increased sweating), fatigue, decreased libido, palpitations, and anxiety.

Adverse events are formally grouped by System-Organ-Class, including Gastrointestinal Disorders, Nervous System Disorders, Psychiatric Disorders, and Reproductive System Disorders.

Documented Serious Adverse Reactions and Safety Notes

The regulatory labels specifically cite risks of clinically significant adverse reactions. These include the potential for Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions, and the risk of Suicidal Thoughts and Behaviors, particularly in children, adolescents, and young adults. Other serious risks noted are Abnormal Bleeding/Hemorrhage, Hyponatremia (low sodium levels), and Seizures.

Official safety notes exist for specific patient populations. Older adults may face a greater risk of developing Hyponatremia. For pediatric and adolescent patients, official documents note an increased risk of suicidal thinking and behavior. Furthermore, the risk of suicidal thoughts and behaviors may be elevated in the early stages of treatment or during dosage adjustments. The medicine is contraindicated for concurrent use with Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Eleva

Property Official Regulatory Statement
Documented overdose presentations Overdose symptoms are typically related to the central nervous system effects of the drug, including somnolence, dizziness, tremor, nausea, and tachycardia (increased heart rate).
Physiological systems affected (as stated in label) Primarily affects the Central Nervous System (CNS) and the cardiovascular system, with documented risks including seizures, coma, and QTc interval prolongation.
Dose-related or exposure-related factors (if applicable) While ingestions of Eleva alone are rarely fatal, deaths have been reported in cases involving Eleva taken in combination with other drugs and/or alcohol.
Emergency-response statements (as written in official documents) Any overdosage should be medically treated aggressively. Patients must contact a poison control center or emergency services immediately upon suspicion.
When immediate medical help is required (label-derived phrasing only) Emergency medical care is required when the individual has collapsed, had a seizure, or exhibits signs of severe toxicity.
Property Official Regulatory Statement
Severity classification (as defined in official documents) The officially documented severe outcomes include Serotonin Syndrome and coma.
Regulatory basis (EMA / FDA / etc.) Information is derived from authoritative sources like the FDA Prescribing Information and the EMA Summary of Product Characteristics.
Overdose-context constraints (as defined in official documents) No specific antidote is known for Eleva overdose.

Resulting Overdose Structure

Official overdose statements:

  • Overdose manifestations are often related to exaggerated serotonergic effects and require critical observation.
  • The most severe risk is Serotonin Syndrome, along with the potential for seizures and serious QTc prolongation.
  • Management must be symptomatic and supportive, and cardiac monitoring is officially recommended.

Connection to the Overall Overdose Profile

The official regulatory profile defines the overdose situation by detailing the specific, potentially severe systemic effects, such as Serotonin Syndrome and cardiac complications, which necessitate immediate and aggressive medical intervention. This profile strictly mandates that patients seek immediate medical attention for any suspected overdose due to these life-threatening risks, informing medical professionals that treatment must focus on supportive measures as no specific antidote is known.

Therapeutic Uses of Eleva

Consistent with its therapeutic profile, Eleva (Sertraline) is commonly used across conditions presenting with episodic or fluctuating manifestations that involve heightened physiological stress and neurological activity.

Eleva helps address symptom clusters that may become intense or disruptive in conditions such as Major Depressive Disorder (MDD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD), and Obsessive-Compulsive Disorder (OCD). It is applied in addressing situations where symptoms create noticeable functional strain, including profound loss of energy and debilitating panic attacks. The medication supports the management of symptoms that interfere with daily comfort.

“It helps patients cope more steadily with symptom fluctuations during difficult episodes.”

Quick Fact: Relief for Intrusive Thoughts

Eleva may assist with reducing the overall burden of persistent, intrusive thoughts and the associated repetitive behaviors, which may be part of symptomatic management for OCD.

This therapeutic action contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability when symptoms are more noticeable, supporting general well-being.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eleva (Sertraline) eligibility is determined by specific regulatory criteria concerning age, concurrent medication use, and existing medical conditions. Use is generally established for adults (18 years and older) for all labeled indications. In pediatric patients, Eleva is approved for the treatment of Obsessive-Compulsive Disorder (OCD) only in children and adolescents aged 6 to 17 years. Use for all other conditions in this age group is not established by regulatory authorities.

Contraindicated Populations

Eleva must not be used by patients who have a known hypersensitivity to Sertraline or its components. It is also contraindicated for patients who are currently taking or have recently stopped a Monoamine Oxidase Inhibitor (MAOI), including linezolid, and those taking Pimozide.

Conditional Eligibility and Restrictions

Population Group Regulatory Status
Severe Hepatic Impairment Not recommended due to insufficient clinical data.
Mild to Moderate Hepatic Impairment Use with caution; requires clinical monitoring.
Geriatric Patients Use with caution due to potential for lower clearance.
Pregnancy (Third Trimester) Associated with regulatory warnings regarding potential neonatal effects.

No dose adjustment is typically required for patients with renal impairment. Patients with conditions like untreated anatomically narrow angles (a risk factor for glaucoma) should avoid the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Eleva (sertraline) interacts with various medicines and substances, which requires careful review and, in some cases, a strict avoidance of combination.

Contraindicated Combinations

The most significant interaction involves Monoamine Oxidase Inhibitors (MAOIs), including selective, irreversible, and reversible MAOIs, as well as drugs with MAOI activity such as linezolid (an antibiotic) and intravenous methylene blue. Combining Eleva with an MAOI is strictly forbidden due to the high risk of a potentially life-threatening condition called Serotonin Syndrome (SS). A minimum 14-day waiting period is required when switching between Eleva and an MAOI. The combination with the antipsychotic medicine pimozide is also contraindicated due to the potential for increased exposure to pimozide and the risk of serious heart rhythm changes (QTc prolongation).

Combinations Requiring Caution

Concomitant use of Eleva with other serotonergic drugs—including certain triptans, opioids (like tramadol and fentanyl), amphetamines, and the herbal supplement St John’s Wort—can also increase the risk of Serotonin Syndrome and must be monitored closely or avoided. Use with medicines that affect blood clotting or function, such as aspirin, NSAIDs, and warfarin, may elevate the risk of bleeding. Caution is also advised when combining Eleva with drugs known to prolong the QTc interval or other antipsychotic agents, or with phenytoin (an antiepileptic medicine), due to possible increased exposure to these agents.

Mechanism of Action

Selective Reuptake Inhibition of Serotonin

Eleva acts primarily by binding to and blocking the Serotonin Transporter (SERT) on the presynaptic membrane, thereby inhibiting the reuptake of the neurotransmitter serotonin (5-HT) from the synapse. This core action immediately increases the availability and concentration of 5-HT in the space between neurons, initiating the entire mechanistic cascade.


Adaptive CNS Homeostasis and Cascade

The initial increase in 5-HT forces the brain into a state of adaptive modulation. This process involves the desensitization of inhibitory autoreceptors (such as 5-HT1A) over a period of weeks, which functionally enhances 5-HT release and maintains the enhanced signaling. This slow adjustment is essential for establishing the sustained physiological changes resulting from the adaptive process.


Neuroplasticity and Functional Remodeling

Chronic modulation of the serotonergic system promotes neuroplasticity by increasing the expression of Brain-Derived Neurotrophic Factor (BDNF) in key regions of the CNS. This mechanism supports the structural and functional remodeling of neuronal circuits in affective regions, contributing to the ultimate physiological modulation of the activity within the brain's affective circuitry.

Dosage and Administration Information

Eleva (Sertraline) is administered exclusively by the oral route, available as tablets in strengths of 25 mg, 50 mg, and 100 mg, or as an oral concentrate solution. The dosing regimen is standardized as once daily, and tablets may be taken either with or without food.

Standard treatment protocols define the starting dose based on the condition being addressed. For most adult indications, including Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD), the initial dose is 50 mg per day. For conditions such as Panic Disorder or Post-Traumatic Stress Disorder (PTSD), the starting dose is 25 mg daily, which is then increased to 50 mg after one week.

Dose adjustments, if necessary, must be incremental, typically in 25 mg or 50 mg steps, and must be separated by an interval of at least one week to ensure the medicine reaches a steady state. The maximum recommended daily dosage across most adult indications is 200 mg.

Specific Administration Conditions:

Usage Context Official Guideline
Hepatic Impairment Recommended starting and maximum doses are half the usual amount.
Oral Concentrate Must be diluted immediately before administration with specific approved liquids (e.g., water, orange juice, lemon/lime soda).
Missed Dose The missed dose should be skipped if it is closer to the time of the next scheduled dose; the dose should not be doubled.

Treatment is typically sustained, and the labeled protocol requires discontinuation via a process of gradual dose reduction (tapering) rather than an abrupt cessation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eleva

The research on Eleva (Sertraline) has focused on what studies explored regarding conditions characterized by fluctuating or episodic manifestations. The evidence available comes primarily from Randomized Controlled Trials (RCTs), where researchers compare the medicine to an inactive placebo, as well as Systematic Reviews and Meta-analyses that combine data from many individual studies.


Evidence for Major Depressive Disorder (MDD) and Prevention

Studies exploring Eleva's role in MDD involved two distinct phases: acute treatment and long-term prevention. Research was conducted during periods of increased symptom activity in adult outpatients, including studies that examined patients with certain comorbid medical conditions.

For acute treatment, short-term RCTs (typically lasting 6 to 12 weeks) were used in research to evaluate the change in symptoms over time. These studies monitored outcomes related to functional imbalance, focusing on validated clinical scales that measure the intensity of depressive symptoms and rates of remission. When results from many studies are pooled into meta-analyses, some reports highlight that the measured change was sometimes minimal compared to control groups.

For long-term use, maintenance studies were applied in research contexts involving patients with a history of recurrent episodes. The research describes that studies monitored the time until recurrence, reporting patterns observed in participants remaining on Eleva compared to control groups. However, the results apply only to the populations studied, and there is limited information for long-term outcomes that fully characterize stability beyond the trial periods.


Evidence for Anxiety Disorders: Panic Disorder, SAD, and GAD

Eleva was studied for several anxiety disorders. These studies focus on short to intermediate-term follow-up and research examined outcomes related to symptom intensity or variability.

  • Panic Disorder: Research for this condition involved RCTs that specifically monitored the frequency of panic attacks and changes in generalized anxiety symptoms. These trials reported patterns related to attack frequency and symptom change compared to control groups.
  • Social Anxiety Disorder (SAD): Studies for SAD primarily used short-term RCTs (around 12 weeks) focusing on outcomes reflecting daily functioning or activity level in adults. Follow-up durations were limited in many of these trials.
  • General Anxiety Disorder (GAD): Eleva was evaluated in a less extensive body of RCTs. The evidence quality varies across studies, and data for long-term outcomes remain insufficient.

Evidence for Obsessive-Compulsive Disorder (OCD) and Post-Traumatic Stress Disorder (PTSD)

  • Obsessive-Compulsive Disorder (OCD): The evidence base for OCD includes research that examined adults, adolescents, and children. Long-term Continuation Studies up to two years were conducted. Research describes patterns observed where studies used a longer time frame and higher dosages in the context of the trials compared to research for MDD.
  • Post-Traumatic Stress Disorder (PTSD): Eleva was studied for PTSD using RCTs designed to measure changes in symptom severity. Findings were mixed across some trials, and research highlights that the measured response may vary across specific trauma types.

Research Gaps and Areas of Scientific Uncertainty

Certain research limitation frames are acknowledged. Data for certain groups remain insufficient for many uses, including some comorbidity-defined groups. For conditions like GAD and SAD, the primary evidence relies on short-term follow-up durations, meaning there is limited information for long-term outcomes characterizing stability beyond that period. In conditions like PTSD, evidence quality varies across studies, and this evidence highlights where certainty remains low for specific subgroups.

Key Studies & References

  1. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis (MDD Evidence)
  2. NICE guideline [NG222]: Depression in adults: treatment and management (Clinical Guideline)

Frequently Asked Questions (FAQ)

Common questions about Eleva (FAQ)

Q: How long does it typically take for a person to start feeling the full benefits of Eleva?

A: Studies and official information indicate that Eleva works through an adaptive process in the brain that requires sustained use. This therapeutic action takes time, meaning it may take several weeks of consistent administration for the full therapeutic effect to manifest.


Q: What conditions, besides depression, is Eleva sometimes prescribed for?

A: According to the official product information, Eleva is approved for the treatment of Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (Social Phobia), and Premenstrual Dysphoric Disorder (PMDD) in adults.


Q: Can Eleva be used for treating social anxiety or panic attacks?

A: Yes, Eleva is approved by regulatory authorities for the treatment of both Panic Disorder and Social Anxiety Disorder (also called Social Phobia) in adults.


Q: Is feeling more anxious or having trouble sleeping normal during the initial weeks of taking Eleva?

A: The regulatory label lists side effects like anxiety and insomnia (trouble sleeping) as common or very common occurrences. Regulatory documents indicate these effects are common and may be more pronounced early in treatment.


Q: Is there a risk of becoming dependent on Eleva if it is taken for a long time?

A: Official product information does not use the term 'dependence' but requires that treatment be discontinued by a process of gradual dose reduction, or tapering. The requirement for a slow reduction is to mitigate the risk of discontinuation symptoms.


Q: What is the general protocol for stopping Eleva treatment once a person is feeling better?

A: Official protocols require that Eleva be stopped via a process of gradual dose reduction (tapering). Abrupt cessation is not recommended, and official protocols require this slow reduction to reduce the risk of adverse reactions.


Q: Can older adults use Eleva safely, or is there a greater risk of certain side effects?

A: Official safety notes advise caution in geriatric patients. This is due to a potential for lower drug clearance and an increased risk of developing Hyponatremia (a condition where sodium levels in the blood are too low).


Q: What is the difference between Eleva and other commonly prescribed SSRI medications?

A: Eleva, which contains the active ingredient sertraline, is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Official documentation highlights that it is chemically unrelated to many other drugs within the SSRI class, though it shares the common mechanism of blocking serotonin reuptake.


Q: Is Eleva known to cause excessive sweating as a side effect?

A: Yes, regulatory documents list Hyperhidrosis (increased or excessive sweating) as a Common side effect. This means it is expected to occur in more than 1 in 100 patients.


Q: How does Eleva affect one's ability to drive or operate machinery?

A: Since common side effects include drowsiness and dizziness, official patient information cautions that Eleva may impair a person's ability to drive a car or operate dangerous machinery. Patients are generally advised to understand how the medicine affects them before engaging in activities that require full alertness.


Q: Is it normal to experience dizziness or drowsiness when taking Eleva?

A: Yes, official safety information indicates that both Dizziness and Somnolence (drowsiness) are listed as Common side effects. This means they are expected reactions that occur in a notable percentage of people taking the medicine.


Q: What kind of studies have been done on Eleva's effectiveness for its approved uses?

A: The evidence supporting Eleva’s effectiveness is derived primarily from Randomized Controlled Trials (RCTs) where the drug is compared to a placebo. This data is often analyzed further through Systematic Reviews and Meta-analyses that combine results from multiple studies.


Q: What are the long-term effects of taking Eleva for several years?

A: Regulatory documents state that while continuation studies have been conducted for some conditions, such as OCD, much of the available evidence relies on short-term follow-up durations. As a result, there is limited long-term information fully characterizing stability and outcomes beyond the trial periods.


Q: Does Eleva interact with alcohol, and what are the potential consequences?

A: Official guidance indicates that the use of alcohol is generally not recommended while taking Eleva. Furthermore, the oral concentrate liquid formulation contains alcohol and has specific contraindications with certain other medicines.


Q: Can Eleva cause changes in vision, such as blurred vision?

A: Official regulatory labels include warnings regarding the potential for developing angle-closure glaucoma. The official label highlights this potential, and patients may be advised about the associated risks, which can include changes in vision like blurred vision or eye pain.


Q: Why do doctors closely monitor patients for suicidal thoughts when starting Eleva?

A: Eleva carries a regulatory Boxed Warning about the risk of Suicidal Thoughts and Behaviors, especially in children, adolescents, and young adults. This risk is noted to be elevated during the early stages of treatment or when the dosage is changed.


Q: Are there common withdrawal symptoms people report when reducing their dose of Eleva?

A: Regulatory information notes that if the dose is reduced too quickly, people may report symptoms such as dizziness, nausea, headache, insomnia, anxiety, and tingling sensations (paresthesia). This is why a gradual dose reduction (tapering) is required.


Q: Are there different brand names for the same active ingredient as Eleva?

A: Yes, the active ingredient in Eleva is sertraline. Sertraline is available globally under several different brand names, which are detailed in official regulatory drug databases.


Q: Can Eleva affect sexual function, and if so, how common are these side effects?

A: Yes, the regulatory label lists sexual side effects. Common side effects include decreased libido in both men and women, and ejaculation failure in men.


Q: What are the concerns about taking Eleva while breastfeeding?

A: Official safety data confirms that Eleva passes into breast milk in small amounts. Healthcare providers must weigh the potential risks and benefits, and the regulatory guidance is that the infant should be monitored for any possible adverse effects.


Q: Can men and women be prescribed Eleva for the same conditions?

A: Yes, men and women can be prescribed Eleva for the treatment of most approved conditions, including Major Depressive Disorder, OCD, Panic Disorder, and PTSD. However, it is also approved for the gender-specific condition PMDD in women only.


Q: Is Eleva ever prescribed to children or adolescents, and for what conditions?

A: Official regulatory approval for use in children and adolescents aged 6 to 17 years is limited to the treatment of Obsessive-Compulsive Disorder (OCD) only. Use for all other conditions in this age group is not currently established.


Q: Are there certain existing medical conditions, like heart problems or glaucoma, that might prevent someone from using Eleva?

A: Official warnings note that Eleva is contraindicated in patients with untreated anatomically narrow angles (a risk factor for angle-closure glaucoma). Caution is also advised in patients with certain heart conditions, such as unstable heart disease or those that affect heart rhythm.


Q: Does Eleva need to be taken with food, or can it be taken on an empty stomach?

A: The official administration instructions state that Eleva tablets may be taken either with food or without food.


Q: If a dose of Eleva is missed, what is the usual recommendation?

A: According to the official drug information, if a dose is missed, you should skip that dose if the next scheduled dose is closer. The dose should not be doubled to make up for the missed one.


Q: Do Eleva tablets come in different strengths or forms?

A: Yes, Eleva is available as oral tablets in different strengths, typically 25 mg, 50 mg, and 100 mg. It is also available as an oral concentrate liquid solution.


Q: Does Eleva affect blood pressure or heart rate?

A: Palpitations (abnormal heart rhythm) are listed as a Common side effect. Caution is advised for individuals with unstable heart disease or conditions that affect heart rhythm, but while palpitations are common, generalized effects on blood pressure are not prominently listed as a common adverse reaction in the regulatory profile.


Q: What type of healthcare professional is typically qualified to prescribe Eleva?

A: Eleva is a prescription-only medicine and must be prescribed by a healthcare professional who is licensed to diagnose and treat the conditions for which the medicine is indicated, such as a doctor, psychiatrist, or other authorized prescriber.


Q: Is Eleva effective for Post-Traumatic Stress Disorder (PTSD)?

A: Yes, Eleva is an approved treatment for Post-Traumatic Stress Disorder (PTSD). Official information notes that findings were mixed across some research trials, indicating that individual response may vary.


Q: How soon after stopping a Monoamine Oxidase Inhibitor (MAOI) can a person start taking Eleva?

A: Official warnings state that a minimum of a 14-day waiting period is strictly required after stopping a Monoamine Oxidase Inhibitor (MAOI) before a person can start taking Eleva. This is due to the high risk of a serious drug interaction.


Q: How to Store and Dispose of Eleva?

A: Eleva tablets must be stored at controlled room temperature (20 C to 25 C), protected from heat and moisture, and kept in the original container. For disposal, unused or expired medicine should be returned via a medicine take-back program or disposed of according to local guidelines, and generally should not be flushed down the toilet, unless explicitly instructed by official local guidance.

How should Eleva be stored and disposed of?

How to Store and Dispose of Eleva (Sertraline)

Official regulatory documents define strict conditions for the storage and disposal of Eleva (Sertraline) to maintain product stability.

Storage and Handling Requirements

Eleva tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medicine must be protected from high heat and moisture and should be kept in its original container, which must be tightly closed.

Disposal and Safety

For safety, the product must be stored out of the sight and reach of children.

Unused or expired Eleva should be disposed of by utilizing a medicine take-back program when available. To prevent environmental contamination, the product should not be flushed down a sink or toilet unless explicitly instructed by official guidance. Disposal must align with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Eleva found in:

A-Z Index: